Granules India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GRANULES, BSE:532482 Granules India Ltd.

Granules India Ltd.

03 Aug 2021

581.85

0.37%

GRANULES INDIA

Buy: Granules India Ltd.

Target

Geojit BNP Paribas

Granules continued its impressive performance in Q1FY22 with total revenues growing by 16% YoY to Rs.849cr despite the myriad of challenges posed by various business scenarios in the backdrop of covid and logistics disruptions. Strong revenue share from the existing molecules and a sizeable...

Granules India Ltd. is trading above all available SMAs

Granules India Ltd.

29 Jul 2021

581.85

0.37%

Granules lndia

Buy: Granules India Ltd.

Target

ICICI Securities Limited

...

Granules India Ltd. is trading above all available SMAs

Granules India Ltd.

29 Jul 2021

581.85

0.37%

On track to build product pipeline as well as capacity

Buy: Granules India Ltd.

Target

Motilal Oswal

Granules India (GRAN) delivered a better-than-expected 1QFY22 performance, led by better off-take in the Intermediates (PFI) and Finished Dosage (FD) segments. The impact of the sharp rise in key starting materials (KSM) for Paracetamol was offset by controlled opex, driving better-thanexpected profitability during the quarter. The improved availability of KSMs and new launches would further enhance the performance going forward. We marginally tweak our EPS estimate for FY22/FY23E, factoring in a) the easing of the supply situation for KSMs and b) higher logistic costs. We continue to value GRAN at 15x 12M forward earnings to arrive at TP of...

Number of FII/FPI investors decreased from 199 to 189 in Sep 2025 qtr

Granules India Ltd.

29 Jul 2021

581.85

0.37%

BP Equities Granules India Ltd Q1FY22 Result Update

Buy: Granules India Ltd.

BP Wealth

increase in KSM prices (mainly PAP) and loss of MEIS benefit (~150bps). Favourable forex and Air freight collected from customers was part of Sales which was added to Gross margin in Stock Q1FY21. However, EBITDA Margin managed lesser impact (decline of 126bps to 23.7% in Q1FY22 ) CMP (INR) due to lower other expenses (-4%YoY). GIL reported a PAT of INR 1202mn, which was above our Target Price (INR) estimate of INR 1018mn driven by ordinary operational performance. As per management, the KSM BSE code supply situation is likely to improve with an increase in the number of domestic suppliers and the recommencement of supply from the Chinese source. The management has stated that it is looking to decrease the share of core molecules from 84% currently to 60% by FY25 with focusing on launching higher-margin products across different geographies....

Number of FII/FPI investors decreased from 199 to 189 in Sep 2025 qtr

Granules India Ltd.

14 May 2021

581.85

0.37%

GRANULES INDIA

Buy: Granules India Ltd.

Recommendation Target

Geojit BNP Paribas

revenues growing by 33% YoY to Rs.799cr in Q4FY21. All segments saw strong growth mainly on the back of of successful new launches, increase in market share of finished dosages, as well as customer additions for APIs and PFIs. Disruption in supply of key raw materials from China will impact operating performance in the short term The company has guided a Capex of ~Rs.1,000cr over the next 3 years as it looks to expand capacities for its key products...

Granules India Ltd. is trading above all available SMAs

Granules India Ltd.

12 May 2021

581.85

0.37%

BP Equities Granules India Ltd Q4FY21 Result Update

Buy: Granules India Ltd.

Target

BP Wealth

Healthy Q4; Input cost increase to dent margin in the near term Granules (GIL) posted revenues of INR 7993mn with 33.2% YoY growth, which was 3.7% above our estimate of INR 7710mn. Revenue growth was mainly driven by an increase in the market share of existing products, new customer additions in the API segment and increasing penetration of PFIs as a category. During Q4, FDs grew by 34% (YoY), PFIs grew by 85% (YoY) and API sales were up by 9%(YoY). Better realisations across our existing molecules and new launches contributed to the increase in gross margins by 378bps (YoY). Subsequently, the EBITDA margin expanded by 861bps to a 25.3% level was 167bps higher than our estimate. EBITDA Margin improvement was mainly on account of higher sales and volumes over a lower base of the previous year. The low base of the previous year was...

Granules India Ltd. has an average target of 632.00 from 4 brokers.

Granules India Ltd.

12 May 2021

581.85

0.37%

Strong end to FY21; on track to develop product/add capacity

Buy: Granules India Ltd.

Target

Motilal Oswal

GRAN delivered an in line performance in 4Q and posted its highest ever sales/EBITDA/PAT on an annual basis in FY21. This was largely led by strong traction in ingredients (PFIs) and formulations (FDs). While the company is on track to expand capacity/develop products, a sharp increase in prices of select key starting materials (KSM) may hinder its near-term performance. We lower our FY22E/FY23E EPS estimate by 11%/10% to factor in a price increase/reduced availability of KSM like para-aminophenol (PAP)/acetic anhydride and lower operating leverage. We value GRAN at 15x 12-months...

Number of FII/FPI investors decreased from 199 to 189 in Sep 2025 qtr

Granules India Ltd.

29 Jan 2021

581.85

0.37%

BP Equities Granules India Ltd Q3FY21 Result Update

Buy: Granules India Ltd.

Target

BP Wealth

Granules (GIL) posted revenues of INR 8445mn with 20% YoY growth, which was ~16% above our estimate of INR 7279mn. Revenue growth was mainly driven by increase in the market share of existing products, new customer additions in the API segment and increasing penetration of PFIs as a category. During Q3, FDs grew by 11% (YoY), PFIs grew by 48% (YoY) and API sales were up by 20%(YoY). Gross margin improved (300bps YoY) due to favourable product mix (larger share of FDs and PFIs) and higher capacity utilization. Subsequently, the EBITDA margin expanded by 188bps to 25.1% level was 145bps higher than our estimate supported by improved operational efficiency. As per management EBITDA margin can be sustained between 25% to 27% level as continued traction in the formulation business. GIL reported PAT of INR 1468mn, was above our estimate of INR 993mn...

Mutual Funds have decreased holdings from 12.24% to 6.54% in Sep 2025 qtr

Granules India Ltd.

29 Jan 2021

581.85

0.37%

Granules lndia

Buy: Granules India Ltd.

ICICI Securities Limited

Revenues grew 20% YoY to | 845 crore driven by new launches and higher market share of existing products across segments. Formulations grew 11% YoY to | 422 crore, API grew 20% to | 252 crore and PFI grew 48% to | 171 crore. EBITDA margins improved 187 bps YoY to 25.1% due to change in product mix and higher operational efficiency. EBITDA grew 29.7% YoY to | 212 crore. Adjusted PAT grew 52.8% YoY to | 147 crore. Delta vis-a-vis EBITDA was due to higher other income (one-time | 13.4 crore stimulus...